Differential responsiveness of the platelet biomarkers, systemic CD40 ligand, CD62P, and platelet-derived growth factor-BB, to virally-suppressive antiretroviral therapy

dc.contributor.authorSteel, Helen Carolyn
dc.contributor.authorVenter, Willem Daniel Francois
dc.contributor.authorTheron, Annette J.
dc.contributor.authorAnderson, Ronald
dc.contributor.authorFeldman, Charles
dc.contributor.authorArulappan, Natasha
dc.contributor.authorRossouw, Theresa M.
dc.date.accessioned2022-02-25T12:04:05Z
dc.date.available2022-02-25T12:04:05Z
dc.date.issued2021-01-29
dc.description.abstractSystemic biomarkers of inflammation, including cytokines and chemokines, are potentially useful in the management of both HIV infection and non-AIDS-defining disorders. However, relatively little is known about the utility of measurement of circulating biomarkers of platelet activation as a strategy to monitor the efficacy of combination antiretroviral therapy (cART), as well as the persistence of systemic inflammation following virally-suppressive therapy in HIV-infected persons. These issues have been addressed in the current study to which a cohort consisting of 199 HIV-infected participants was recruited, 100 of whom were cART-naïve and the remainder cART-treated and virally suppressed. Fifteen healthy control participants were included for comparison. The study focused on the effects of cART on the responsiveness of three biomarkers of platelet activation, specifically soluble CD40 ligand (sCD40L), sCD62P (P-selectin), and platelet-derived growth factor-BB (PDGF-BB), measured using multiplex suspension bead array technology. Most prominently sCD40L in particular, as well as sCD62P, were significantly elevated in the cART-naïve group relative to both the cART-treated and healthy control groups. However, levels of PDGF-BB were of comparable magnitude in both the cART-naïve and –treated groups, and significantly higher than those of the control group. Although remaining somewhat higher in the virally-suppressed group relative to healthy control participants, these findings identify sCD40L, in particular, as a potential biomarker of successful cART, while PDGF-BB may be indicative of persistent low-level antigenemia.en_ZA
dc.description.departmentImmunologyen_ZA
dc.description.librarianam2022en_ZA
dc.description.sponsorshipA National Health Laboratory Service Development Grant; the Bill and Melinda Gates Foundation; the South African Department of Health; South African Medical Research Council and the National Research Foundation of South Africa.en_ZA
dc.description.urihttp://www.frontiersin.org/Immunologyen_ZA
dc.identifier.citationSteel, H.C., Venter, W.D.F., Theron, A.J., Anderson, R., Feldman, C., Arulappan, N. & Rossouw, T.M. (2021) Differential Responsiveness of the Platelet Biomarkers, Systemic CD40 Ligand, CD62P, and Platelet-Derived Growth Factor-BB, to Virally-Suppressive Antiretroviral Therapy. Frontiers in Immunology 11:594110. DOI: 10.3389/fimmu.2020.594110.en_ZA
dc.identifier.issn1664-3224 (online)
dc.identifier.other10.3389/fimmu.2020.594110
dc.identifier.urihttp://hdl.handle.net/2263/84235
dc.language.isoenen_ZA
dc.publisherMDPIen_ZA
dc.rights© 2021 Steel, Venter, Theron, Anderson, Feldman, Arulappan and Rossouw. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).en_ZA
dc.subjectBiomarkersen_ZA
dc.subjectNon-AIDS-defining disordersen_ZA
dc.subjectPlateletsen_ZA
dc.subjectPlatelet-derived growth factor BBen_ZA
dc.subjectSoluble CD40 liganden_ZA
dc.subjectSoluble CD62Pen_ZA
dc.subjectAntiretroviral therapy (ART)en_ZA
dc.subjectHuman immunodeficiency virus (HIV)en_ZA
dc.subjectCombination antiretroviral therapy (cART)en_ZA
dc.titleDifferential responsiveness of the platelet biomarkers, systemic CD40 ligand, CD62P, and platelet-derived growth factor-BB, to virally-suppressive antiretroviral therapyen_ZA
dc.typeArticleen_ZA

Files

Original bundle

Now showing 1 - 3 of 3
Loading...
Thumbnail Image
Name:
Steel_Differential_2021.pdf
Size:
664.34 KB
Format:
Adobe Portable Document Format
Description:
Article
Loading...
Thumbnail Image
Name:
Steel_DifferentialTabS1_2021.docx
Size:
457.49 KB
Format:
Microsoft Word XML
Description:
Table S1
Loading...
Thumbnail Image
Name:
Steel_DifferentialTabS2_2021.docx
Size:
216.19 KB
Format:
Microsoft Word XML
Description:
Table S2

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: